8-K - Candel Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Other Event

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement On February 19, 2026, Candel Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underw

Material Agreement

$5.45$93.5M$107.6M

8.01

. Other Events. On February 19, 2026, the Company issued press releases announcing the launch and the pricing of the Offering. Copies of the press releases are

Other Event

$93.5M

9.01

. Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement dated February 19, 2026. 5.1 Opinion of Goodwin Procter LLP

Exhibits Only

Source Document

Exhibits (5)

1.1

EX-1.1

5.1

EX-5.1

8-K

99.1

EX-99.1

99.2

EX-99.2